Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Detergent) (SPR verified)

Customer Reviews
Cat. No. / Size
Price
Qty
CD0-H82E5-20ug
$1235.00
CD0-H82E5-100ug
$3965.00
ETA of in-stock products:2 business days

Product Details

  • Application

    1. Immunization
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Detergent Biotinylated Human CD20 Full Length, His,Avitag (CD0-H82E5) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met 1

    Request for sequence
  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.9 kDa. The protein migrates as 40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    *The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Each full-length transmembrane protein is encapsulated by detergent micelle.

    2. Synthesis Process

      Through mild detergent micelle extraction, dedicated solubilization, and stringent affinity purification, we maximally retain the native transmembrane conformation of full-length transmembrane proteins throughout downstream purification. This workflow yields purified, detergent-solubilized proteins free of unrelated membrane impurities and exogenous scaffold proteins, with exceptional purity, accurate quantitation, and well-preserved biological activity—ideal for immunization, binding assays in antibody discovery and screening (ELISA) and affinity testing (SPR and BLI), etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    This product is not suitable for cell based experiments due to cytotoxicity of DDM.
    DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
    DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
    If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    CD20 SDS-PAGE

    Biotinylated Human CD20 Full Length, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Rituximab biosimilar (Cat. No. CD0-M36) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) with a linear range of 1-15.625 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) with a linear range of 4-63 ng/mL (in presence of DDM and CHS) (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Obinutuzumab with a linear range of 1.2-2 ng/mL (Routinely tested).

    Protocol
  •  CD20 ELISA

    Immobilized Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) at 1 μg/mL, add Glofitamab and then add Biotinylated Human CD20 Protein (Cat. No. CD0-H82E5) at 0.1 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

    Protocol
  • Bioactivity-SPR

     CD20 SPR

    Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) captured on Biotin CAP-Series S Sensor Chip can bind Rituximab with an affinity constant of 1.73 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (QC tested).

    Protocol
  •  CD20 SPR

    Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) captured on Biotin CAP-Series S Sensor Chip can bind Ofatumumab (Human IgG1) with an affinity constant of 1.03 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (QC tested).

    Protocol
  •  CD20 SPR

    Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) captured on Biotin CAP-Series S Sensor Chip can bind Obinutuzumab with an affinity constant of 0.721 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     CD20 BLI

    Loaded Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) on SA Biosensor, can bind Rituximab with an affinity constant of 0.247 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  CD20 BLI

    Loaded Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) on SA Biosensor, can bind Ofatumumab (Human IgG1) with an affinity constant of 0.277 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  CD20 BLI

    Loaded Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E5) on SA Biosensor, can bind Biosimilar of Obinutuzumab with an affinity constant of 0.197 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

Recent Advances

 
Drug Development Progress
  • English Name:

    B-lymphocyte antigen CD20

  • Category:

  • Approved Drugs:

    35 Details

  • Drugs in Clinical Trials:

    132 Details

  • Highest Development Stage:

    Approved

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8